Search details
1.
Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer.
Stem Cells
; 2024 Apr 02.
Article
in English
| MEDLINE | ID: mdl-38563224
2.
High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset.
Mod Pathol
; 37(5): 100472, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38492778
3.
Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw
; 22(3): 140-150, 2024 04.
Article
in English
| MEDLINE | ID: mdl-38626801
4.
Somatic loss of ATM is a late event in pancreatic tumorigenesis.
J Pathol
; 260(4): 455-464, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37345735
5.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Cancer
; 129(14): 2169-2178, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-37060201
6.
ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins.
Mod Pathol
; 36(7): 100147, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36828362
7.
Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.
Mod Pathol
; 36(10): 100247, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37307876
8.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(10): 1067-1096, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37856213
9.
GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
J Pathol
; 257(2): 158-171, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35072947
10.
P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
J Pathol
; 256(2): 149-163, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34652816
11.
Clinical and genomic features of SPOP-mutant prostate cancer.
Prostate
; 82(2): 260-268, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34783071
12.
Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.
Prostate
; 82(16): 1505-1519, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35971807
13.
Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Cancer
; 128(12): 2269-2280, 2022 06 15.
Article
in English
| MEDLINE | ID: mdl-35333400
14.
Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Cancer Immunol Immunother
; 71(4): 943-951, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34533610
15.
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
J Natl Compr Canc Netw
; 20(12): 1288-1298, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36509074
16.
Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes.
J Pathol
; 253(4): 415-426, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33338262
17.
Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.
J Pathol
; 255(4): 425-437, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34431104
18.
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Oncologist
; 26(2): e270-e278, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33215787
19.
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Mod Pathol
; 34(6): 1185-1193, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33462368
20.
PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.
Histopathology
; 78(2): 327-333, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32740981